Save Product
Product Details
Synonym
Glycoprotein E/gE (VZV)
Source
Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (GLE-V52H3) is expressed from human 293 cells (HEK293). It contains AA Ser 31 - Ala 546 (Accession # Q9J3M8-1).
Predicted N-terminus: Ser 31
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 60.2 kDa. The protein migrates as 54-69 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) is more than 95% and the molecular weight of this protein is around 60-85 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) at 1 μg/mL (100 μL/well) can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) with a linear range of 0.08-1 ng/mL (QC tested).
Protocol
Bioactivity-SPR
Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 4.81 nM as determined in SPR assay (Biacore 8K) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing